It is approved in the United States, the European Union and Japan for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome. It also raised its revenue forecast to a range of $2.22 billion to $2.23 billion, from its prior view of $2.18 to $2.20 billion. Alexion's net income rose to $177.7 million, or 88 cents per share, in the...
Oct 23- Alexion Pharmaceuticals Inc reported a better-than-expected adjusted profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year. The company raised its full-year 2014 adjusted earnings per share forecast to $5.15 to $5.20 per share from $4.95 to $5.05 per share.
CHESHIRE, Conn. _ Alexion Pharmaceuticals Inc. on Thursday reported third-quarter net income of $177.7 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.14 per share. Analysts expected $541.8 million, according to Zacks.
LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.
NEW YORK, June 26- U.S. healthcare companies are winning higher profit forecasts, bucking a wider trend on Wall Street, as pricey new biotech drugs hit the market and insurance enrollment rises under the Affordable Care Act.
June 2- Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain. The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.
*Hewlett-Packard's revenue misses Wall St estimates. Among momentum names, noted for high growth and perceptions of excessive valuation, Vertex Pharmaceuticals shares shot up 6 percent to $71.18, while Alexion Pharmaceuticals rose 2.5 percent to $160.48.
This quarter's earnings have a clear trend: they either beat expectations or report in-line, which does little to help the stock.
This ETF has been the tip of the arrow when it comes to trading momentum stocks.
Some of Wednesday's midday movers:
The tumble of once highflying tech stocks signals a potential shift in investors chasing eye-popping growth, the New York Times reports.
On a terrible day for the Nasdaq 100, a third of its decline can be pegged on three much-loved stocks.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Some of Tuesday's midday movers:
There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.
Some of Monday's midday movers:
Some of the names on the move ahead of the open.
Talk about following the money. Investors looking to beat the S&P 500 need only track companies that are spending the most money lobbying Washington.
Some of Thursday's midday movers:
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.